

ALASKA MEDICAID  
Prior Authorization Criteria

**Veozah<sup>®</sup>**  
**(fezolinetant)**

**FDA INDICATIONS AND USAGE**<sup>1</sup>

Veozah<sup>®</sup> is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

**APPROVAL CRITERIA**<sup>1,2,3,4</sup>

1. Patient meets FDA labeled age **AND**;
2. Patient has a diagnosis of menopause with moderate to severe vasomotor symptoms **AND**;
3. Baseline liver function tests have been performed **AND**;
4. Prescriber attests that follow up liver function tests will be performed as outlined in FDA approved prescribing information **AND**;
5. Patient has tried and failed at least one agent from the following categories or has a contraindication to both of the following:
  - a. Hormone therapy (e.g. oral, transdermal, etc.)
  - b. Non-hormone therapy (e.g. venlafaxine, paroxetine, etc.)

**DENIAL CRITERIA**<sup>1</sup>

1. Failure to meet approval criteria **OR**;
2. Patient has a diagnosis of cirrhosis **OR**;
3. Baseline total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels are elevated  $\geq 2$  times the upper limit of normal (ULN) **OR**;
4. Patient has severe renal impairment or end-stage renal disease.

**CAUTIONS**<sup>1</sup>

- Elevations in serum transaminase concentrations  $> 3$  times the upper limit of normal have occurred.
- Use in combination with CYP1A2 inhibitors is not advised.

**DURATION OF APPROVAL**

- Initial Approval: up to 3 months
- Reauthorization Approval: up to 12 months

**QUANTITY LIMIT**

- 34 tablets for 34 days

ALASKA MEDICAID  
Prior Authorization Criteria

**REFERENCES / FOOTNOTES:**

1. Veozah [prescribing information]. Northbrook, IL; Astellas; August 2024.
2. Faubion SS, Crandall CJ, Davis L, et al. The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause*. 2022; 29(7):767-794. DOI: 10.1097/GME.0000000000002028. Available at: <https://menopause.org/publications/professional-publications/position-statements-other-reports>.
3. The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. *Menopause*. 2023; 30(6): 573-590: DOI: 10.1097/GME.0000000000002200. Available at: <https://www.menopause.org/publications/professional-publications/position-statements-other-reports>.
4. Beaudoin FL, McQueen RB, Wright A, et al. Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value; final evidence report. Institute for Clinical and Economic Review. January 23, 2023. Available at: <https://icer.org/assessment/vasomotor-symptoms-menopause-2022/#overview>.